Systemic Epstein–Barr virus‐positive T‐cell lymphoma of childhood treated with the ICE regimen and allogeneic hematopoietic stem‐cell transplantation

Nagahama, Jun; Nishikawa, Takuro; Tasaki, Takashi; Yasudome, Yuki; Nakamura, Tatsuro; Abematsu, Takanari; Nakagawa, Shunsuke; Kodama, Yuichi; Tanimoto, Akihide; Okamoto, Yasuhiro

doi:10.1002/pbc.30041

Cited by 5 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Case reports have demonstrated successful treatment with SMILE (dexamethasone, methotrexate, L-asparaginase, etoposide) and ICE (ifosfamide, carboplatin, etoposide) chemotherapeutic regimens, followed by hematopoietic stem cell transplant (HSCT). 6,7 Pre-transplant conditioning in these reports consisted of myeloablative approaches with cyclophosphamide or busulfan. 6,7 Outcomes remain guarded, with S-EBV-TCL often rapidly progressing to multiorgan failure, sepsis, and death.…”

Section: Introductionmentioning

confidence: 99%

“…6,7 Pre-transplant conditioning in these reports consisted of myeloablative approaches with cyclophosphamide or busulfan. 6,7 Outcomes remain guarded, with S-EBV-TCL often rapidly progressing to multiorgan failure, sepsis, and death. 3,6 We present a case in which a 20 month old female was diagnosed with HLH and S-EBV-TCL was successfully treated with chemotherapy and HSCT.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hematopoietic Bone Marrow Transplant to Treat Systemic EBV-positive T-Cell Lymphoma of Childhood

Manini¹,

Davidow²,

Conard³

et al. 2023

Preprint

View full text Add to dashboard Cite

Systemic EBV positive T-cell lymphoma of childhood (S-EBV-TCL) is a rare disease for which there is no standard of care. S-EBV-TCL is often associated with hemophagocytic lymphohistiocytosis (HLH) and is generally thought of on the spectrum of Epstein-Barr Virus (EBV) related disease. For the few reported cases of cure in the literature, hematopoietic stem cell transplant (HSCT) has been required. Here, we present the case of one patient who was successfully cured with a modified regimen of dose adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), followed by HSCT using a reduced intensity conditioning regimen.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Hematopoietic Bone Marrow Transplant to Treat Systemic EBV-positive T-Cell Lymphoma of Childhood

Manini¹,

Davidow²,

Conard³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Case reports have demonstrated successful treatment with SMILE (dexamethasone, methotrexate, L-asparaginase, etoposide) and ICE (ifosfamide, carboplatin, etoposide) chemotherapeutic regimens, followed by hematopoietic stem cell transplant (HSCT). 6,7 HSCT is necessary in S-EBV-TCL due to the significant risk of relapse. Ideally, a transplant occurs <30 months after disease onset with the disease in remission at that time.…”

mentioning

confidence: 99%

“…8 Pretransplant conditioning in previous case reports consisted of myeloablative approaches with cyclophosphamide or busulfan. 6,7 Outcomes remain guarded, with S-EBV-TCL often rapidly progressing to multiorgan failure, sepsis, and death. 3,6 No standard of care, including upfront chemotherapy and conditioning for transplant, currently exists for S-EBV-TCL due to its rarity.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Hematopoietic Bone Marrow Transplant to Treat Systemic EBV-positive T-cell Lymphoma of Childhood

Manini,

Davidow,

Conard

et al. 2023

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Systemic Epstein-Barr virus–positive T-cell lymphoma of childhood (S-EBV-TCL) is a rare disease for which there is no standard of care. S-EBV-TCL is often associated with hemophagocytic lymphohistiocytosis and is generally thought of on the spectrum of EBV-related disease. For the few reported cases of cure in the literature, hematopoietic stem cell transplant has been required because it is the only treatment that has induced complete remission in patients suffering from EBV-associated T-cell or natural killer cell lymphoproliferative diseases, except hemophagocytic lymphohistiocytosis. Here, we present the case of one patient who was successfully cured with a modified regimen of dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), followed by hematopoietic stem cell transplant using a reduced-intensity conditioning regimen.

show abstract

Multiple drugs

2023

Reactions Weekly

View full text Add to dashboard Cite

Systemic Epstein–Barr virus‐positive T‐cell lymphoma of childhood treated with the ICE regimen and allogeneic hematopoietic stem‐cell transplantation

Cited by 5 publications

References 11 publications

Hematopoietic Bone Marrow Transplant to Treat Systemic EBV-positive T-Cell Lymphoma of Childhood

Hematopoietic Bone Marrow Transplant to Treat Systemic EBV-positive T-Cell Lymphoma of Childhood

Hematopoietic Bone Marrow Transplant to Treat Systemic EBV-positive T-cell Lymphoma of Childhood

Multiple drugs

Contact Info

Product

Resources

About